Stock Financial Ratios, Dividends, Split History

BTN / Ballantyne Strong, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.25
Volume3,500.00
Market Cap ($M)75.72
Enterprise Value ($M)72.88
Book Value / Share3.06
Price / Book1.72
NCAV ($M)7.35
NCAV / Share0.51
Price / NCAV10.30
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 14,251,000
Common Shares Outstanding 14,422,090
Weighted Average Number Of Diluted Shares Outstanding 14,251,000
Common Stock Shares Outstanding 14,422,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.08
Return on Assets (ROA)-0.06
Return on Equity (ROE)-0.08
Balance Sheet (mrq) ($M)
Assets59.01
Liabilities14.89
Quick Ratio2.01
Current Ratio2.56
Income Statement (mra) ($M)
Sales Revenue Net72,646,000.00
Sales Revenue Services Net25,102,000.00
Equity Method Investment Summarized Financial Information Revenue72,325,000.00
Sales Revenue Goods Net47,544,000.00
Disposal Group Including Discontinued Operation Revenue24,000.00
Operating Income-2.81
Net Income-3.62
Earnings Per Share Basic-0.25
Earnings Per Share Diluted-0.25
Cash Flow Statement (mra) ($M)
Cash From Operations-0.11
Cash from Investing-5.41
Cash from Financing-5.41
Identifiers and Descriptors
CUSIP058516105
Central Index Key (CIK)946454

Split History

Stock splits are used by Ballantyne Strong, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

BRIEF-Ballantyne Strong Unit Enteres Into Contract Of Sale For A Sale-Leaseback Transaction Of CMS S Office Facility

2018-05-01 reuters
* BALLANTYNE STRONG INC - UNIT ENTERED INTO CONTRACT OF SALE FOR A SALE-LEASEBACK TRANSACTION OF CMS S OFFICE FACILITY IN ALPHARETTA, GEORGIA (2-0)

CUSIP: 058516105